Security Snapshot

Athira Pharma, Inc. - Common Stock, $0.0001 Par Value (ATHA) Institutional Ownership

CUSIP: 04746L104

13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

0

Shares (Excl. Options)

0

Price

$0.38

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, $0.0001 Par Value
Symbol
ATHA on Nasdaq
Shares outstanding
9,614,000
Price per share
$0.38
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
0
Total reported value
$0
Share change
-1,052
Value change
-$595
Number of holders
0
Price from insider filings
$0.38
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • ATHA - Athira Pharma, Inc. - Common Stock, $0.0001 Par Value is tracked under CUSIP 04746L104.
  • 0 institutions reported positions in Q4 2025.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 2 to 0 between Q3 2025 and Q4 2025.
  • Reported value moved from $595 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 0 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 04746L104?
CUSIP 04746L104 identifies ATHA - Athira Pharma, Inc. - Common Stock, $0.0001 Par Value in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Athira Pharma, Inc. - Common Stock, $0.0001 Par Value (ATHA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ACORN BIOVENTURES, L.P. 6.2% +20% $1,345,504 +$212,929 596,068 +19% Anders Hove 06 Jan 2026
Oliveira Steven Michael 4.1% -20% $69,324 -$788,375 161,218 -92% Oliveira Steven Michael 01 Oct 2025

As of 31 Dec 2025, 0 institutional investors reported holding 0 shares of Athira Pharma, Inc. - Common Stock, $0.0001 Par Value (ATHA). This represents 0% of the company’s total 9,614,000 outstanding shares.

Institutional Holders of Athira Pharma, Inc. - Common Stock, $0.0001 Par Value (ATHA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$595 $0.38 0
2025 Q3 1,052 $595 -$5,301,419 $2.26 2
2025 Q2 17,548,824 $5,295,638 +$4,106 $0.30 50
2025 Q1 17,565,344 $5,002,785 -$111,730 $0.28 52
2024 Q4 17,923,414 $10,513,884 +$1,168,387 $0.59 54
2024 Q3 16,127,357 $7,192,159 -$16,853,612 $0.45 56
2024 Q2 22,193,550 $58,807,500 +$1,275,233 $2.65 65
2024 Q1 21,695,406 $59,443,068 -$117,105 $2.74 73
2023 Q4 21,901,553 $53,218,137 -$1,833,437 $2.43 64
2023 Q3 21,432,485 $43,293,241 -$1,354,746 $2.02 70
2023 Q2 21,887,314 $64,565,994 -$5,409,932 $2.95 76
2023 Q1 23,800,339 $59,500,190 +$2,342,756 $2.50 81
2022 Q4 21,791,013 $69,074,070 +$2,745,077 $3.17 92
2022 Q3 22,084,894 $65,591,691 +$171,025 $2.97 94
2022 Q2 21,955,517 $66,960,232 -$100,026,928 $3.05 89
2022 Q1 26,114,392 $352,431,678 +$183,845 $13.50 99
2021 Q4 26,188,389 $341,210,519 +$17,550,511 $13.03 97
2021 Q3 24,890,216 $233,607,844 +$136,180 $9.38 91
2021 Q2 24,736,986 $253,318,555 -$61,367,283 $10.24 86
2021 Q1 26,338,783 $484,401,324 +$83,845,702 $18.40 68
2020 Q4 21,510,354 $733,206,641 +$29,318,645 $34.25 69
2020 Q3 21,658,200 $395,426,446 +$395,426,446 $18.46 54